Compare Jones Lang LaSalle Inc (JLL) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jones Lang LaSalle Inc vs TG Therapeutics Inc — how do they compare? Jones Lang LaSalle Inc trades at $325.67 (market cap $15.12B), while TG Therapeutics Inc trades at $54.31 (market cap $8.26B). The key difference: Jones Lang LaSalle Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Jones Lang LaSalle Inc nearer its low. Which is the better fit depends on your goals.
| JLL | TGTX | |
|---|---|---|
Market Cap | $15.12B | $8.26B |
Sector | Real Estate | Health |
52-Week High | $358.66 | $59.06 |
52-Week Low | $253.48 | $26.39 |
Enterprise Value | $18.66B | $8.50B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
